Apixaban Reduced Risk for Stroke, Embolism in Patients Ineligible for Vitamin K Antagonist

Stuart J. Connolly, MD et al, The New England Journal of Medicine

Results from the AVERROES study showed that apixaban reduced the risk for stroke or systemic embolism without simultaneously increasing risk for major bleeding or intracranial hemorrhage in patients with atrial fibrillation who did not respond to treatment with vitamin K antagonist.

In a double blind, international study funded by Bristol-Myers Squibb and Pfizer, researchers recruited 5,599 patients at 522 centers in 36 countries. Enrollment began in September 2007 and ended in December 2009.

Read more…


All active news articles

Get Involved

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.